{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:14:33Z","timestamp":1783466073702,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Body Image"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.bodyim.2007.12.003","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T19:20:01Z","timestamp":1204831201000},"page":"13-27","source":"Crossref","is-referenced-by-count":151,"title":["Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach"],"prefix":"10.1016","volume":"5","author":[{"given":"Katharine A.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bodyim.2007.12.003_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00004583-199904000-00019","article-title":"33 cases of body dysmorphic disorder in children and adolescents","volume":"38","author":"Albertini","year":"1999","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/00004583-199611000-00010","article-title":"Body dysmorphic disorder in a young child (letter)","volume":"35","author":"Albertini","year":"1996","journal-title":"Journal of the American Academy Child and Adolescent Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib3","series-title":"6th International Obsessive Compulsive Disorder Conference Abstracts","article-title":"An open-label trial of venlafaxine in body dysmorphic disorder","author":"Allen","year":"2003"},{"key":"10.1016\/j.bodyim.2007.12.003_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0006-3223(00)00831-3","article-title":"The relationship of obsessive compulsive disorder to possible spectrum disorders: Results from a family study","volume":"48","author":"Bienvenu","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00005053-199008000-00014","article-title":"Body dysmorphic disorder: The relationship to obsessive-compulsive disorder","volume":"178","author":"Brady","year":"1990","journal-title":"Journal of Nervous and Mental Disorders"},{"key":"10.1016\/j.bodyim.2007.12.003_bib6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials","volume":"15","author":"Bridge","year":"2007","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.bodyim.2007.12.003_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1176\/ajp.151.2.288a","article-title":"Response of major depression with psychosis and body dysmorphic disorder to ECT (letter)","volume":"151","author":"Carroll","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10578-006-0008-7","article-title":"Body dysmorphic disorder and other clinically significant body image concerns in adolescent psychiatric inpatients: Prevalence and clinical characteristics","volume":"36","author":"Dyl","year":"2006","journal-title":"Child Psychiatry and Human Development"},{"key":"10.1016\/j.bodyim.2007.12.003_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1176\/ajp.155.1.102","article-title":"The Brown Assessment of Beliefs Scale: reliability and validity","volume":"155","author":"Eisen","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.comppsych.2003.09.010","article-title":"Insight in obsessive compulsive disorder and body dysmorphic disorder","volume":"45","author":"Eisen","year":"2004","journal-title":"Comprehensive Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/00004583-199511000-00004","article-title":"Sertraline for body dysmorphic disorder (letter)","volume":"34","author":"El-Khatib","year":"1995","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF00800664","article-title":"Epidemiology of somatoform disorders: A community survey in Florence","volume":"32","author":"Faravelli","year":"1997","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1016\/j.bodyim.2007.12.003_bib13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","article-title":"Early evidence on the effects of regulators\u2019 suicidality warnings on SSRI prescriptions and suicide in children and adults","volume":"164","author":"Gibbons","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1176\/appi.ajp.164.7.1044","article-title":"Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets","volume":"164","author":"Gibbons","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib15","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1176\/appi.ajp.163.11.1898","article-title":"The relationship between antidepressant prescription rates and rate of early adolescent suicide","volume":"163","author":"Gibbons","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4088\/JCP.v62n07a03","article-title":"Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients","volume":"62","author":"Grant","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0010-440X(03)00088-9","article-title":"Axis I comorbidity in body dysmorphic disorder","volume":"44","author":"Gunstad","year":"2003","journal-title":"Comprehensive Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1192\/bjp.116.533.399","article-title":"Dysmorphophobia","volume":"116","author":"Hay","year":"1970","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00004583-199707000-00004","article-title":"SSRI for body dysmorphic disorder (letter)","volume":"36","author":"Heimann","year":"1997","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archpsyc.56.11.1033","article-title":"Clomipramine vs. desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness","volume":"56","author":"Hollander","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3928\/0048-5713-19930701-06","article-title":"Body dysmorphic disorder","volume":"23","author":"Hollander","year":"1993","journal-title":"Psychiatric Annals"},{"key":"10.1016\/j.bodyim.2007.12.003_bib22","first-page":"75","article-title":"Fluvoxamine treatment of body dysmorphic disorder (letter)","volume":"14","author":"Hollander","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.bodyim.2007.12.003_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1176\/ajp.146.6.768","article-title":"Treatment of body dysmorphic disorder with serotonin reuptake blockers","volume":"146","author":"Hollander","year":"1989","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.mp.4000712","article-title":"Adult brain neurogenesis and psychiatry: A novel theory of depression","volume":"5","author":"Jacobs","year":"2000","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib25","series-title":"Abstracts, National Institute of Mental Health NCDEU 44th Annual Meeting","first-page":"231","article-title":"A chart-review study of SRI continuation treatment versus discontinuation in body dysmorphic disorder","author":"Jain","year":"2004"},{"key":"10.1016\/j.bodyim.2007.12.003_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0887-6185(97)00020-0","article-title":"Comparison of clinical characteristics in obsessive-compulsive disorder and body dysmorphic disorder","volume":"11","author":"McKay","year":"1997","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1016\/j.bodyim.2007.12.003_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/070674378202700504","article-title":"Monosymptomatic hypochondriacal psychosis: A diagnostic checklist based on 50 cases of the disorder","volume":"27","author":"Munro","year":"1982","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib28","series-title":"Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder (A guideline from the National Institute for Health and Clinical Excellence, National Health Service)","author":"National Collaborating Centre for Mental Health","year":"2006"},{"key":"10.1016\/j.bodyim.2007.12.003_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0005-7967(00)00053-X","article-title":"Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders","volume":"39","author":"Neziroglu","year":"2001","journal-title":"Behavior Research and Therapy"},{"key":"10.1016\/j.bodyim.2007.12.003_bib30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1176\/appi.ajp.158.12.2061","article-title":"Prevalence of body dysmorphic disorder in a community sample of women","volume":"158","author":"Otto","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1017\/S1092852900002650","article-title":"Intravenous, pulse-loaded clomipramine in body dysmorphic disorder: Two case reports","volume":"1","author":"Pallanti","year":"1996","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.bodyim.2007.12.003_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004850-199612000-00006","article-title":"Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia)","volume":"11","author":"Perugi","year":"1996","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.bodyim.2007.12.003_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ajp.148.9.1138","article-title":"Body dysmorphic disorder: The distress of imagined ugliness","volume":"148","author":"Phillips","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib34","first-page":"175","article-title":"An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder","volume":"32","author":"Phillips","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.bodyim.2007.12.003_bib35","first-page":"597","article-title":"Pharmacologic treatment of body dysmorphic disorder","volume":"32","author":"Phillips","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.bodyim.2007.12.003_bib36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00005053-200003000-00007","article-title":"Quality of life for patients with body dysmorphic disorder","volume":"188","author":"Phillips","year":"2000","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1016\/j.bodyim.2007.12.003_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3956(03)00098-0","article-title":"Psychosis in body dysmorphic disorder","volume":"38","author":"Phillips","year":"2004","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.bodyim.2007.12.003_bib38","series-title":"The broken mirror: Understanding and treating body dysmorphic disorder","author":"Phillips","year":"2005"},{"key":"10.1016\/j.bodyim.2007.12.003_bib39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.162.2.377","article-title":"A placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder","volume":"162","author":"Phillips","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.yic.0000194378.65460.ef","article-title":"An open-label study of escitalopram in body dysmorphic disorder","volume":"21","author":"Phillips","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.bodyim.2007.12.003_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archpsyc.59.4.381","article-title":"A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder","volume":"59","author":"Phillips","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4088\/JCP.v62n0910","article-title":"Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study","volume":"62","author":"Phillips","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4088\/JCP.v66n0607","article-title":"Suicidal ideation and suicide attempts in body dysmorphic disorder","volume":"66","author":"Phillips","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib44","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00005053-199709000-00006","article-title":"Gender differences in body dysmorphic disorder","volume":"185","author":"Phillips","year":"1997","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1016\/j.bodyim.2007.12.003_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4088\/JCP.v59n0404","article-title":"Efficacy and safety of fluvoxamine in body dysmorphic disorder","volume":"59","author":"Phillips","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib46","first-page":"17","article-title":"A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale","volume":"33","author":"Phillips","year":"1997","journal-title":"Psychopharmacological Bulletin"},{"key":"10.1016\/j.bodyim.2007.12.003_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v62n0203","article-title":"Delusionality and response to open-label fluvoxamine in body dysmorphic disorder","volume":"62","author":"Phillips","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib48","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1176\/ajp.150.2.302","article-title":"Body dysmorphic disorder: 30 cases of imagined ugliness","volume":"150","author":"Phillips","year":"1993","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib49","first-page":"179","article-title":"A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases","volume":"30","author":"Phillips","year":"1994","journal-title":"Psychopharmacological Bulletin"},{"key":"10.1016\/j.bodyim.2007.12.003_bib50","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1176\/appi.ajp.163.7.1280","article-title":"Suicidality in body dysmorphic disorder: A prospective study","volume":"163","author":"Phillips","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.comppsych.2004.10.004","article-title":"Psychosocial functioning and quality of life in body dysmorphic disorder","volume":"46","author":"Phillips","year":"2005","journal-title":"Comprehensive Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/appi.psy.46.4.317","article-title":"Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder","volume":"46","author":"Phillips","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bodyim.2007.12.003_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpsychires.2005.08.005","article-title":"Delusional versus nondelusional body dysmorphic disorder: Clinical features and course of illness","volume":"40","author":"Phillips","year":"2006","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.bodyim.2007.12.003_bib54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4088\/JCP.v64n0615","article-title":"An open-label study of citalopram in body dysmorphic disorder","volume":"64","author":"Phillips","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00005053-199602000-00012","article-title":"Prevalence and clinical features of body dysmorphic disorder in atypical major depression","volume":"184","author":"Phillips","year":"1996","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1016\/j.bodyim.2007.12.003_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/10401230600948464","article-title":"Pharmacotherapy for body dysmorphic disorder: Treatment received and illness severity","volume":"18","author":"Phillips","year":"2006","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/da.20232","article-title":"Obsessive-compulsive disorder versus body dysmorphic disorder: A comparison study of two possibly related disorders","volume":"24","author":"Phillips","year":"2007","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.bodyim.2007.12.003_bib58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.psy.45.5.438","article-title":"Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study","volume":"45","author":"Phillips","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bodyim.2007.12.003_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:PSAQ.0000043507.03596.0d","article-title":"Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder","volume":"75","author":"Phillips","year":"2004","journal-title":"Psychiatric Quarterly"},{"key":"10.1016\/j.bodyim.2007.12.003_bib60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0033-3182(97)71400-2","article-title":"Muscle dysmorphia: An under recognized form of body dysmorphic disorder","volume":"38","author":"Pope","year":"1997","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bodyim.2007.12.003_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1017\/S0033291706007264","article-title":"The prevalence of body dysmorphic disorder: A population-based survey","volume":"36","author":"Rief","year":"2006","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.bodyim.2007.12.003_bib62","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/01.psy.0000163455.43226.bf","article-title":"Pharmacologic treatment of depression in patients with heart disease","volume":"67","author":"Roose","year":"2005","journal-title":"Psychosomatic Medicine"},{"key":"10.1016\/j.bodyim.2007.12.003_bib63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0893-133X(99)00082-2","article-title":"Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder","volume":"21","author":"Saxena","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bodyim.2007.12.003_bib64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.164.7.1029","article-title":"Suicide attempts among patients starting depression treatment with medications or psychotherapy","volume":"164","author":"Simon","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004583-198803000-00010","article-title":"Clomipramine treatment of delusional disorder, somatic type","volume":"27","author":"Sondheimer","year":"1988","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib66","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archpsyc.62.7.792","article-title":"Effects of antidepressant mediation on morbidity and mortality in depressed patients after myocardial infarction","volume":"62","author":"Taylor","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1192\/bjp.169.2.196","article-title":"Body dysmorphic disorder: A survey of fifty cases","volume":"169","author":"Veale","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.bodyim.2007.12.003_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.brat.2004.12.006","article-title":"A meta-analysis of psychological treatments for Body Dysmorphic Disorder","volume":"44","author":"Williams","year":"2006","journal-title":"Behaviour Research and Therapy"},{"key":"10.1016\/j.bodyim.2007.12.003_bib69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0010-440X(98)90034-7","article-title":"Body dysmorphic disorder in psychiatric outpatients: Recognition, prevalence, comorbidity, demographic, and clinical correlates","volume":"39","author":"Zimmerman","year":"1998","journal-title":"Comprehensive Psychiatry"}],"container-title":["Body Image"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174014450800003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174014450800003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T15:21:50Z","timestamp":1557328910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174014450800003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S174014450800003X"],"URL":"https:\/\/doi.org\/10.1016\/j.bodyim.2007.12.003","relation":{},"ISSN":["1740-1445"],"issn-type":[{"value":"1740-1445","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}